The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: A meta-analysis of randomized clinical trials

DOI Web Site 参考文献9件
  • Abdelazeem Basel
    Department of Internal Medicine, McLaren Health Care, Flint, Michigan, USA. Michigan State University, East Lansing, Michigan, USA.
  • Elbadawy Merihan A.
    Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
  • Awad Ahmed K.
    Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
  • Kheiri Babikir
    Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Kunadi Arvind
    Department of Internal Medicine, McLaren Health Care, Flint, Michigan, USA.

この論文をさがす

説明

<p>Recently, a few randomized control trials (RCTs) suggested that finerenone has been shown to reduce cardiovascular events in patients with CKD and DM-2. We aimed to analyze the cardiovascular benefits of using finerenone in patients with CKD and DM-2. Electronic databases were systematically searched to identify only RCTs comparing finerenone versus placebo. Pooled risk ratios (RR) and their 95% confidence intervals (CI) were calculated using random-effects models. Three RCTs were included, with a total of 13,847 patients. Compared with the placebo group, the use of finerenone was associated with significantly lower rates of cardiovascular events (RR: 0.88; 95% CI: 0.80, 0.96; p < 0.01), which was mainly driven by lower hospitalizations for heart failure (RR: 0.79; 95% CI: 0.66, 0.94; p = 0.01). However, there were no significant differences between groups in terms of cardiovascular death (RR: 0.88; 95% CI: 0.76, 1.02; p = 0.09), non-fatal myocardial infarction (RR: 0.91; 95% CI: 0.74, 1.12;p = 0.38), non-fatal stroke (RR: 0.99; 95% CI: 0.80, 1.22; p = 0.90). </p>

収録刊行物

  • Intractable & Rare Diseases Research

    Intractable & Rare Diseases Research 11 (1), 31-33, 2022-02-28

    特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会

参考文献 (9)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ